A pathway profile-based method for drug repositioning

Chinese Science Bulletin

Volumn 57, Issue 17, 2012, Pages 2106-2112

  Ye, Hao ^a,b   Yang, Lin Lin ^a,b   Cao, Zhi Wei ^c   Tang, Kai Lin ^b   Li, Yi Xue ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

drug repositioning; drug disease relationship; pathway profile; pharmacological function

Indexed keywords

EID: 84862804815     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-012-4982-9     Document Type: Article

References (73)

1. Adams C P, Brantner V V. Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood), 2006, 25: 420-428.
2. Krantz A. Protein-site targeting. Diversification of the drug discovery process. Nat Biotechnol, 1998, 16: 1294.
3. Day M. The bitterest pill. Nurs Times, 1996, 92: 16-17.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov, 2004, 3: 711-715.
5. Calabrese L, Fleischer A B. Thalidomide: Current and potential clinical applications. Am J Med, 2000, 108: 487-495.
6. Amato R J. Thalidomide: An antineoplastic agent. Curr Oncol Rep, 2002, 4: 56-62.
7. Matthews S J, McCoy C. Thalidomide: A review of approved and investigational uses. Clin Ther, 2003, 25: 342-395.
8. Gasparini G, Morabito A, Magnani E, et al. Thalidomide: An old sedative-hypnotic with anticancer activity? Curr Opin Investig Drugs, 2001, 2: 1302-1308.
9. Ashburn T T, Thor K B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov, 2004, 3: 673-683.
10. Chong C R, Sullivan D J Jr. New uses for old drugs. Nature, 2007, 448: 645-646.
11. Keiser M J, Setola V, Irwin J J, et al. Predicting new molecular targets for known drugs. Nature, 2009, 462: 175-181.
12. Campillos M, Kuhn M, Gavin A C, et al. Drug target identification using side-effect similarity. Science, 2008, 321: 263-266.
13. Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA, 2010, 107: 14621-14626.
14. He L, Luo H, Chen J, et al. DRAR-CPI: A server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res, 2011, 39: W492-W498.
15. Drews J. Drug discovery: A historical perspective. Science, 2000, 287: 1960-1964.
16. Paolini G V, Shapland R H, van Hoorn W P, et al. Global mapping of pharmacological space. Nat Biotechnol, 2006, 24: 805-815.
17. Barabasi A L, Oltvai Z N. Network biology: Understanding the cell's functional organization. Nat Rev Genet, 2004, 5: 101-113.
18. Barabasi A L, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet, 2011, 12: 56-68.
19. Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res, 2010, 38: D355-360.
20. Li Y, Agarwal P. A pathway-based view of human diseases and disease relationships. PLoS ONE, 2009, 4: e4346.
21. Davis A P, King B L, Mockus S, et al. The comparative toxicogenomics database: Update 2011. Nucleic Acids Res, 2011, 39: D1067-1072.
22. Feldman S R, Kimball A B, Krueger G G, et al. Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. J Am Acad Dermatol, 2005, 53: 887-889.
23. De Smit M J, Brouwer E, Vissink A, et al. Rheumatoid arthritis and periodontitis: A possible link via citrullination. Anaerobe, 2011, 17: 196-200.
24. Berthelot J M, Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine, 2010, 77: 537-541.
25. Di Paola R, Mazzon E, Muia C, et al. Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol, 2007, 150: 286-297.
26. Swale V J, Perrett C M, Denton C P, et al. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol, 2003, 28: 604-607.
27. Kang M J, Lee Y H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci, 2006, 21: 946-949.
28. Shakoor N, Michalska M, Harris C A, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 2002, 359: 579-580.
29. Madhusudan S, Foster M, Muthuramalingam S R, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res, 2004, 10: 6528-6534.
30. Chernyshov V P, Vodyanik M A, Pisareva S P. Lack of soluble TNF-receptors in women with recurrent spontaneous abortion and possibility for its correction. Am J Reprod Immunol, 2005, 54: 284-291.
31. Winger E E, Reed J L. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol, 2008, 60: 8-16.
32. Rodas J D, Cairo C, Djavani M, et al. Circulating natural killer and gammadelta T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Mem Inst Oswaldo Cruz, 2009, 104: 583-591.
33. Wallace D J. The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: It's time to get serious. J Rheumatol, 2003, 30: 1897-1899.
34. Nabors L B, Suswam E, Huang Y, et al. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuR. Cancer Res, 2003, 63: 4181-4187.
35. Lazner F, Gowen M, Pavasovic D, et al. Osteopetrosis and osteoporosis: Two sides of the same coin. Hum Mol Genet, 1999, 8: 1839-1846.
36. Boyce B F, Li P, Yao Z, et al. TNF-alpha and pathologic bone resorption. Keio J Med, 2005, 54: 127-131.
37. Depinay N, Franetich J F, Gruner A C, et al. Inhibitory effect of TNF-alpha on malaria pre-erythrocytic stage development: Influence of host hepatocyte/parasite combinations. PLoS ONE, 2011, 6: e17464.
38. Maihle N J, Baron A T, Barrette B A, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res, 2002, 107: 247-258.
39. Andersson U, Schwartzbaum J, Wiklund F, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol, 2010, 49: 767-775.
40. Ratushny V, Astsaturov I, Burtness B A, et al. Targeting EGFR resistance networks in head and neck cancer. Cell Signal, 2009, 21: 1255-1268.
41. Begnami M D, Fukuda E, Fregnani J H, et al. HER2 and HER3 are Predictors of poor outcome. J Clin Oncol, 2011, 29: 3030-3036.
42. Delord J P, Quideau S, Rochaix P, et al. Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. Br J Cancer, 2010, 103: 61-72.
43. Mineo J F, Bordron A, Quintin-Roue I, et al. Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br J Cancer, 2004, 91: 1195-1199.
44. Kondo N, Ishiguro Y, Kimura M, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep, 2008, 20: 373-378.
45. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol, 2011, 18: 53-59.
46. Azzoli C G, Krug L M, Miller V A, et al. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol, 2002, 29: 59-65.
47. Langer C J, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol, 2004, 22: 1180-1187.
48. Ferrone M, Motl S E. Trastuzumab for the treatment of non-small-cell lung cancer. Ann Pharmacother, 2003, 37: 1904-1908.
49. John J, Woodward D B, Wang Y, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care, 2010, 25: 270-275.
50. Telli M L, Witteles R M. Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw, 2011, 9: 243-249.
51. Gay S, Gay R E, Koopman W J. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction? Ann Rheum Dis, 1993, 52: S39-S47.
52. Satoh K, Kikuchi S, Sekimata M, et al. Involvement of ErbB-2 in rheumatoid synovial cell growth. Arthritis Rheum, 2001, 44: 260-265.
53. Manger K, Repp R, Jansen M, et al. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: Association with clinical symptoms. Ann Rheum Dis, 2002, 61: 786-792.
54. Brambila-Tapia A J, Davalos-Rodriguez I P. Fcgamma receptor polymorphisms and systemic lupus erythematosus. Rev Invest Clin, 2009, 61: 66-72.
55. Wolf D L, Neiderud A M, Hinckley K, et al. Fcgamma receptor polymorphisms and periodontal status: A prospective follow-up study. J Clin Periodontol, 2006, 33: 691-698.
56. Yamamoto K, Kobayashi T, Grossi S, et al. Association of Fcgamma receptor IIa genotype with chronic periodontitis in Caucasians. J Periodontol, 2004, 75: 517-522.
57. Loos B G, Leppers-van de Straat F G, van de Winkel J G, et al. Fcgamma receptor polymorphisms in relation to periodontitis. J Clin Periodontol, 2003, 30: 595-602.
58. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol, 2008, 26: 1789-1796.
59. Erickson C A, Stigler K A, Posey D J, et al. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics, 2010, 7: 258-263.
60. Pardini M, Guida S, Gialloreti L E. Aripiprazole treatment for coprophagia in autistic disorder. J Neuropsychiatry Clin Neurosci, 2010, 22: e433-451.
61. Blankenship K, Erickson C A, Stigler K A, et al. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years. Ped Health, 2010, 4: 375-381.
62. Marcus R N, Owen R, Manos G, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol, 2011, 21: 229-236.
63. Owen R, Sikich L, Marcus R N, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 2009, 124: 1533-1540.
64. Robb A S, Andersson C, Bellocchio E E, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): Results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord, 2011, 13: PCC. 10m01008.
65. Findling R L, Short E J, Leskovec T, et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adol Psycho-pharmacol, 2008, 18: 347-354.
66. Del Zompo M. Dopaminergic hypersensitivity in migraine: Clinical and genetic evidence. Funct Neurol, 2000, 15: 163-170.
67. Cubo E, Kompoliti K, Leurgans S E, et al. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol, 2004, 27: 30-32.
68. LaPorta L D. Relief from migraine headache with aripiprazole treatment. Headache, 2007, 47: 922-926.
69. Maytal G, Ostacher M, Stern T A. Aripiprazole-related tardive dyskinesia. CNS Spectr, 2006, 11: 435-439.
70. Abbasian C, Power P. A case of aripiprazole and tardive dyskinesia. J Psychopharmacol, 2009, 23: 214-215.
71. Pena M S, Yaltho T C, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord, 2011, 26: 147-152.
72. Kanatous S B, Mammen P P A, Rosenberg P B, et al. Hypoxia reprograms calcium signaling and regulates myoglobin expression. Cell Physiol, 2009, 296: C393-C402.
73. Zhang J Y, Kowal D M, Nawoschik S P, et al. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol, 2006, 71: 521-529.